Avtor/Urednik		Hafner, Matjaž
Naslov		Nov pristop k zdravljenju kroničnega hepatitisa C
Tip		članek
Vir		Gastroenterolog
Vol. in št.		Letnik 7, št. 3
Leto izdaje		2003
Obseg		str. 64-6
Jezik		slo
Abstrakt		Therapy of chronic hepatitis C has greatly improved in recent years. On the basis of available data the highest response rates to antiviral therapy have been achieved using the combination of pegylated interferon and ribavirin. The pegylated forms of interferon allow once-a-week administration and result in more profound supression of virus activity compared to standard interferons. The duration of therapy and the dose of ribavirin should be decided according to the virus genotype. Patients infected with difficult-to-treat genotypes of virus should be treated for 48 weeks - the decision to continue the therapy is based on analysis of the viral response at 12 and 24 weeks, while patients infected with easy-to-treat genotypes should be treated for 24 weeks without intermediate virus testing.
Izvleček		Zdravljenje kroničnega hepatitisa C je v zadnjih letih vse uspešnejše. Rezultati raziskav kažejo, da je najuspešnejše kombinirano protivirusno zdravljenje s pegiliranim interferonom in ribavirinom. Pri pegilirani obliki interferona zadošča apliciranje enkrat tedensko, protivirusni učinek pa je večji kot pri običajnem interferonu. O trajanju zdravljenja in odmerku ribavirina se odločimo glede na genotip virusa. Bolnike okužene z virusi težje ozdravljivih genotipov zdravimo 48 tednov, o nadaljevanju zdravljenja se odločamo na osnovi spremljanja viremije po 12 in 24 tednih zdravljenja. Bolnike okužene z virusi lažje ozdravljivih genotipov zdravimo le 24 tednov, vmesno spremljanje viremije pa ni potrebno.
Deskriptorji		HEPATITIS C HEPATITIS, CHRONIC ACTIVE INTERFERON-ALPHA GENOTYPE